AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20570240 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival rotational flap with intraoperative 0.02% MMC for 2 minutes
Number of subjects: 82
Study 18812325 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (80 mg/day)
Number of subjects: 102
Study 16911386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical methotrexate gel
Number of subjects: 40
Study 16911386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaseline ointment)
Number of subjects: 40
Study 12816908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.39 mg THC/day
Number of subjects: 7
Study 12816908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.47 mg THC/day
Number of subjects: 7
Study 12816908 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg THC/day
Number of subjects: 7
Study 12816908 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.8 mg THC/day
Number of subjects: 7
Study 12816908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg THC/day)
Number of subjects: 7
Study 11053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 15
Study 11053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (4.5 mg/kg)
Number of subjects: 15
Study 11053334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 15
Study 11053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) and Theophylline (4.5 mg/kg)
Number of subjects: 15
Study 8730405 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 23
Study 8730405 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 23
Study 1428268 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 24
Study 1428268 — intervention group
Group type: COMPARATOR
Intervention: Non-amiodarone
Number of subjects: 24
Study 6381186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-amino-salicylic acid (4-ASA) enemas (1 g)
Number of subjects: 52
Study 6381186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-amino-salicylic acid (4-ASA) enemas (2 g)
Number of subjects: 52
Study 6381186 — intervention group
Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 52
Study 31390900 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (weekly group-based sessions over an 8-week period)
Number of subjects: 55
Study 30009632 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-CBT
Number of subjects: 195
Study 30009632 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 195
Study 26556894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 25
Study 26556894 — intervention group
Group type: COMPARATOR
Intervention: Calisthenics-and-breathing exercises
Number of subjects: 25
Study 25459920 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (home visits by case managers at least once a month)
Number of subjects: 153
Study 25459920 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 153
Study 25459920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case management intervention)
Number of subjects: 153
Study 22656396 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Reach Out and Read (ROR) program, receiving anticipatory guidance and an appropriate children's book at a well-baby clinic.
Number of subjects: 415
Study 22656396 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard pediatric outpatient service.
Number of subjects: 415
Study 21510527 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection clonidine 150 mcg
Number of subjects: 60
Study 21510527 — intervention group
Group type: COMPARATOR
Intervention: Injection midazolam 5 mg
Number of subjects: 60
Study 18633172 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 40
Study 18633172 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg
Number of subjects: 40
Study 15711112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia (CEGA)
Number of subjects: 50
Study 15711112 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 50
Study 11919123 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with type 1 diabetes
Number of subjects: 120
Study 11919123 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group of healthy women
Number of subjects: 120
Study 9989964 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 415
Study 9989964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 7482266 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (urokinase)
Number of subjects: 114
Study 7482266 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 114
Study 2246712 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl supplementation (0.01-0.02 ml of 1 N HCl/ml of milk)
Number of subjects: 68
Study 2246712 — intervention group
Group type: COMPARATOR
Intervention: Water supplementation (control)
Number of subjects: 68
Study 6352793 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous treatment
Number of subjects: 7
Study 6352793 — intervention group
Group type: COMPARATOR
Intervention: Traditional intensive insulin therapy
Number of subjects: 7
Study 31248268 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (new users)
Number of subjects: 8018
Study 31248268 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of statins (control group)
Number of subjects: 8018
Study 30630808 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 200
Study 30630808 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 200
Study 27042828 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of sodium intake in women
Number of subjects: 1805
Study 27042828 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of UA and tertile of sodium intake
Number of subjects: 1805
Study 27042828 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of sodium intake in men
Number of subjects: 1805
Study 24269085 — intervention group
Group type: EXPERIMENTAL
Intervention: High IOP (22 to 40 mm Hg)
Number of subjects: 0
Study 24269085 — intervention group
Group type: COMPARATOR
Intervention: Normal IOP (10 to 21 mm Hg)
Number of subjects: 0
Study 23129559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐based Art Therapy (MBAT)
Number of subjects: 18
Study 23129559 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 18
Study 20558922 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 75 mg per meal
Number of subjects: 22
Study 20558922 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg per meal
Number of subjects: 22
Study 18259090 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 73
Study 18259090 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (Inderal)
Number of subjects: 73
Study 18259090 — intervention group
Group type: EXPERIMENTAL
Intervention: aspirin + propranolol
Number of subjects: 73
Study 18259090 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study 16973686 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict rate control (AFFIRM) aiming for resting heart rate <=80 bpm and heart rate during daily activity <=110 bpm
Number of subjects: 1091
Study 16973686 — intervention group
Group type: COMPARATOR
Intervention: Lenient rate control (RACE) aiming for resting heart rate <100 bpm
Number of subjects: 1091
Study 16973686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mean heart rates during AF within the AFFIRM criteria (<=80 bpm)
Number of subjects: 1091
Study 16973686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mean heart rates during AF within the RACE criteria (<100 bpm)
Number of subjects: 1091
Study 15294408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intratracheal insufflation of oxygen (CIO)
Number of subjects: 16
Study 15294408 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV)
Number of subjects: 16
Study 11236242 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring group (parents with type 2 diabetes)
Number of subjects: 56
Study 11236242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no family history of diabetes)
Number of subjects: 56
Study 8910246 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate physical activity level
Number of subjects: 44
Study 8910246 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 44
Study 8910246 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent disability pension
Number of subjects: 44
Study 8910246 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess of major negative life events
Number of subjects: 44
Study 8910246 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom duration
Number of subjects: 44
Study 6241559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (30 micrograms ethinyl estradiol and 150 micrograms levonorgestrel)
Number of subjects: 441
Study 6241559 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-only preparation (75 micrograms dl-norgestrel)
Number of subjects: 441
Study 6241559 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal controls
Number of subjects: 441
Study 6241559 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate
Number of subjects: 441
Study 31713723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol 400 mg/day for 3 months
Number of subjects: 14
Study 31713723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30067592 — intervention group
Group type: EXPERIMENTAL
Intervention: INT‐CYC
Number of subjects: 93
Study 30067592 — intervention group
Group type: EXPERIMENTAL
Intervention: INT‐SWI
Number of subjects: 93
Study 30067592 — intervention group
Group type: EXPERIMENTAL
Intervention: INT‐FOO
Number of subjects: 93
Study 30067592 — intervention group
Group type: COMPARATOR
Intervention: CON‐SWI
Number of subjects: 93
Study 30067592 — intervention group
Group type: COMPARATOR
Intervention: CON‐FOO
Number of subjects: 93
Study 30067592 — intervention group
Group type: COMPARATOR
Intervention: CON‐CYC
Number of subjects: 93
Study 28319422 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-powered pulsed laser/light
Number of subjects: 40
Study 28319422 — intervention group
Group type: EXPERIMENTAL
Intervention: High-powered continuous laser/light
Number of subjects: 40
Study 28319422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28319422 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-powered continuous laser/light
Number of subjects: 40
Study 25054775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month prednisolone treatment
Number of subjects: 255
Study 25054775 — intervention group
Group type: COMPARATOR
Intervention: 6-month prednisolone treatment
Number of subjects: 255
Study 25054775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study 23421353 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (1, 2, 4, 6, 8, and 10 g/70 kg)
Number of subjects: 14
Study 23421353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (12, 24, 48, 72, 96, and 120 g/70 kg)
Number of subjects: 14
Study 23421353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23421353 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB and Ethanol (highest tolerated doses)
Number of subjects: 14
Study 21045655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% PVP-I
Number of subjects: 200
Study 21045655 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PVP-I
Number of subjects: 200
Study 18951663 — intervention group
Group type: EXPERIMENTAL
Intervention: PPVC (Smartsite Plus positive bolus valve)
Number of subjects: 80
Study 18951663 — intervention group
Group type: COMPARATOR
Intervention: Conventional cap
Number of subjects: 80
Study 16877376 — intervention group
Group type: EXPERIMENTAL
Intervention: CLD regimen (75 IU FSH for 14 days with 37.5 IU increment)
Number of subjects: 209
Study 16877376 — intervention group
Group type: COMPARATOR
Intervention: SQ regimen (half of the FSH dose required for follicular development)
Number of subjects: 209
Study 16877376 — intervention group
Group type: EXPERIMENTAL
Intervention: CLD regimen
Number of subjects: 209
Study 16877376 — intervention group
Group type: COMPARATOR
Intervention: SQ regimen
Number of subjects: 209
Study 12826993 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (sertraline)
Number of subjects: 22
Study 12826993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant (nortriptyline)
Number of subjects: 22
Study 10913811 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymers with carmustine
Number of subjects: 0
Study 10913811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8862104 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet nebulizer (WN)
Number of subjects: 95
Study 8862104 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI)
Number of subjects: 95
Study 8862104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WN and MDI
Number of subjects: 95
Study 8862104 — intervention group
Group type: COMPARATOR
Intervention: Self-administration of salbutamol by MDI
Number of subjects: 95
Study 8862104 — intervention group
Group type: COMPARATOR
Intervention: 400-microgram MDI
Number of subjects: 95
Study 8862104 — intervention group
Group type: COMPARATOR
Intervention: MDI therapy with supervision
Number of subjects: 95
Study 1623994 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0-cm contraceptive implant
Number of subjects: 48
Study 1623994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-cm contraceptive implant
Number of subjects: 48
Study 1623994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 48
Study 6435371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glibenclamide treatment
Number of subjects: 20
Study 6435371 — intervention group
Group type: COMPARATOR
Intervention: Insulin and placebo
Number of subjects: 20
Study 30777512 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled exposure to the target talker's audio recordings for 4 days (Experiment 2)
Number of subjects: 0
Study 30777512 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural listening environment with manipulated relationships with the talker (Experiment 1)
Number of subjects: 0
Study 28231835 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg/day)
Number of subjects: 64
Study 28231835 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (2.5 mg bid to a maximal dose of 5 mg bid)
Number of subjects: 64
Study 26147625 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic video
Number of subjects: 194
Study 26147625 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 194
Study 26147625 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative infographic
Number of subjects: 194
Study 26147625 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic infographic
Number of subjects: 194
Study 26147625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 24383441 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tablet-based prenatal psychosocial assessment (e-screening)
Number of subjects: 542
Study 24383441 — intervention group
Group type: COMPARATOR
Intervention: Paper-based screening
Number of subjects: 542
Study 21947373 — intervention group
Group type: EXPERIMENTAL
Intervention: balneotherapy with thermal-mineral water
Number of subjects: 60
Study 21947373 — intervention group
Group type: COMPARATOR
Intervention: tap water (control)
Number of subjects: 60
Study 19265331 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus
Number of subjects: 25
Study 19265331 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIFREE RepleniSH
Number of subjects: 25
Study 19265331 — intervention group
Group type: EXPERIMENTAL
Intervention: Solo‐Care Aqua
Number of subjects: 25
Study 19265331 — intervention group
Group type: EXPERIMENTAL
Intervention: MeniCare Soft
Number of subjects: 25
Study 17852172 — intervention group
Group type: EXPERIMENTAL
Intervention: MITI coding by trained coders after a 4-month training
Number of subjects: 7
Study 17852172 — intervention group
Group type: EXPERIMENTAL
Intervention: MITI coding by trained coders
Number of subjects: 7
Study 15577178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements
Number of subjects: 0
Study 11438404 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9250800 — intervention group
Group type: EXPERIMENTAL
Intervention: Early G-CSF (filgrastim 5 microg/kg/d) from day 4 of IVAP
Number of subjects: 65
Study 9250800 — intervention group
Group type: COMPARATOR
Intervention: Late G-CSF (filgrastim 5 microg/kg/d) from day 15 of IVAP
Number of subjects: 65
Study 8342211 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential suicide prevention program (7 weekly 2-hour meetings)
Number of subjects: 393
Study 8342211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 393
Study 3783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, low‐dose continuous prednisone, and tamoxifen (CMFp + T) for 12 months
Number of subjects: 463
Study 3783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year
Number of subjects: 463
Study 3783203 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment after mastectomy (observation)
Number of subjects: 463
Study 3783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy with CMFp + T
Number of subjects: 463
Study 3783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone with p + T
Number of subjects: 463
Study 3783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (CMFp + T) and observation
Number of subjects: 463
Study 31283740 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior trunk block
Number of subjects: 126
Study 31283740 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 126
Study 27925651 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg/d LNG
Number of subjects: 66
Study 27925651 — intervention group
Group type: EXPERIMENTAL
Intervention: 300, 600, or 1050 μg/d ATZ combined with 40 μg/d LNG
Number of subjects: 66
Study 27925651 — intervention group
Group type: EXPERIMENTAL
Intervention: ATZ in the dose range investigated
Number of subjects: 66
Study 26936876 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 568
Study 26936876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study 24630348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A (BoNT‐A) injections (n = 23)
Number of subjects: 41
Study 24630348 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (n = 18)
Number of subjects: 41
Study 22963982 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 323
Study 22963982 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 323
Study 22963982 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial presentation with ACS
Number of subjects: 323
Study 22963982 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 323
Study 19608026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 307
Study 19608026 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 307
Study 17982194 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment with vitamin D(3), VK(2), and EHDP
Number of subjects: 0
Study 15231925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tymp Aware (physician evaluated tympanometry results)
Number of subjects: 698
Study 15231925 — intervention group
Group type: COMPARATOR
Intervention: Tymp Unaware (physician blinded to tympanometry findings)
Number of subjects: 698
Study 11741360 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2457
Study 11741360 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive strategy
Number of subjects: 2457
Study 10514891 — intervention group
Group type: EXPERIMENTAL
Intervention: New mattress overlay
Number of subjects: 413
Study 10514891 — intervention group
Group type: COMPARATOR
Intervention: Usual perioperative care
Number of subjects: 413
Study 7733075 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d., CBS 120 mg q.i.d. for 7 days
Number of subjects: 61
Study 7733075 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d. (without CBS)
Number of subjects: 61
Study 2282998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg t.i.d. and 400 mg nocte for 6 weeks
Number of subjects: 166
Study 2282998 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine 50 mg b.i.d. for 6 weeks
Number of subjects: 166
Study 2282998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine during follow-up phase
Number of subjects: 166
Study 2282998 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine during follow-up phase
Number of subjects: 166
Study 7305653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 41
Study 31982317 — intervention group
Group type: EXPERIMENTAL
Intervention: Portomesenteric venous intervention
Number of subjects: 42
Study 30794665 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal support (i.e., spouse hand-holding)
Number of subjects: 80
Study 30794665 — intervention group
Group type: COMPARATOR
Intervention: Non-support condition (i.e., alone)
Number of subjects: 80